We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Iovance Biotherapeutics, Inc.
Health Care · Biotechnology
Structural: first-in-class commercial TIL therapy in solid tumors, addressing post-checkpoint melanoma (~20k US patients/yr) with deep, durable responses no other modality delivers. Autologous one-time treatment, ~$515k list price. iCTC manufacturing facility in Philadelphia (Navy Yard) is the throughput chokepoint - revenue scales with slot count, not demand.
(1) Amtagvi ramp accelerating - authorized treatment centers (ATCs) expanding from launch cohort toward 70+; (2) NSCLC + cervical + frontline melanoma combos extend TAM 5-10x if Ph2/3 read out; (3) cash runway extended via Feb 2026 raise; (4) Proleukin acquisition gives captive IL-2 supply, removes cost-of-goods risk; (5) only scaled TIL manufacturer - moat is regulatory + operational, not IP.
(1) launch slower than buyside hoped - ATC onboarding + lymphodepletion logistics gate uptake; (2) 22-day vein-to-vein turnaround + ICU-grade infrastructure caps real-world adoption; (3) cash burn ~$400m/yr against capacity build; (4) competitive pressure from next-gen TIL ($ADAP, Achilles) and bispecifics in melanoma 2L; (5) reimbursement friction at smaller ATCs; (6) micro-cap cell-therapy beta - funding-window risk if rate regime tightens.
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
No major news in the last 7 days for IOVA - only listicles and opinion pieces, which we filter out by default. See everything anyway.